Actavis Launches Griseofulvin Oral Suspension In US
Griseofulvin Oral Suspension
Actavis Group has launched Griseofulvin Oral Suspension in the United States.
Distribution of the product will commence immediately.
Griseofulvin Oral Suspension USP, the generic equivalent of Ortho-McNeil's Grifulvin(R) V, will be available in the 125mg/5mL strength. Griseofulvin is indicated for the treatment of fungal infections of the skin, fingernails and toenails.
Annual sales of Griseofulvin Oral Suspension USP in the U.S. were approximately US$38 million for the twelve months ending March 2007 according to IMS Health data.
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 39 countries, with 11,000 employees.
The company's market capitalization is approximately EUR3.3bn. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market. In the U.S. alone, the company made 38 ANDA filings in 2006 and expects to file 40-45 in the year 2007 along with 18-20 new product launches. The company's U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.